Methods of assaying connective tissue growth factor
OwnerStephen L. Weitz, William R. Usingerinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of detection and quantitation of connective tissue growth factor (CTGF), and diagnosis and detection of various CTGF-associated diseases and disorders.
Claims22
A method for quantitating the level of polypeptide comprising CTGF N-terminal fragment in a sample, the method comprising:
- (a) contacting a sample with a first reagent that specifically binds to a CTGF N-terminal fragment region under conditions suitable for binding;
- (b) isolating the first reagent;
- and
- (c) quantitating the level of polypeptide bound to the first reagent.
A method for diagnosing a CTGF-associated disorder, the method comprising:
- (a) quantitating the level of polypeptide comprising CTGF N-terminal fragment in a sample from a subject;
- and
- (b) comparing the level of polypeptide comprising CTGF N-terminal fragment in the sample with a standard level, wherein an increased or decreased amount of polypeptide comprising CTGF N-terminal fragment in the sample is indicative of the presence of a CTGF-associated disorder.
A method for prognosis of a CTGF-associated disorder, the method comprising:
- (a) quantitating the level of polypeptide comprising CTGF N-terminal fragment in a sample from a subject;
- and
- (b) comparing the level of polypeptide comprising CTGF N-terminal fragment in the sample with a standard level, wherein an increased or decreased amount of polypeptide comprising CTGF N-terminal fragment in the sample is indicative of the presence of a CTGF-associated disorder.
A method for monitoring the progression of a CTGF-associated disorder in a subject, the method comprising:
- (a) obtaining a first sample from the subject at a first point in time;
- (b) obtaining a second sample from the subject at a second point in time;
- (c) quantitating the level of polypeptide comprising CTGF N-terminal fragment in the first and second samples;
- and
- (c) comparing the level of polypeptide comprising CTGF N-terminal fragment in the first sample to the level of polypeptide comprising CTGF N-terminal fragment in the second sample, wherein a difference between the level of polypeptide comprising CTGF N-terminal fragment in the first sample and the level of polypeptide comprising CTGF N-terminal fragment in the second sample is indicative of the progression of a CTGF-associated disorder.
A method for quantitating the level of polypeptide comprising CTGF C-terminal fragment in a sample, the method comprising
- (a) contacting a sample with a first reagent which specifically binds to a C-terminal fragment region under conditions suitable for binding;
- (b) isolating the first reagent;
- (c) adding a second reagent which binds specifically to a CTGF C-terminal fragment region different from the region bound by the first reagent;
- (d) removing unbound second reagent;
- and
- (e) measuring the amount of bound second reagent.
A kit for detecting or quantitating CTGF in a sample, the kit comprising
- (a) a first reagent which binds specifically to a region on CTGF;
- and
- (b) a second reagent which binds specifically to a region on CTGF different from the region bound by the first reagent.
Dependencies are inferred from the claim text.